Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Tislelizumab Combined With Chemoradiotherapy in First-line Treatment of Stage IVb Esophageal Squamous Cell Carcinoma

NCT05547828 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xinxiang Medical College as lead sponsor.

NCT NCT05547828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05547828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Tislelizumab Combined With Chemoradiotherapy in First-line Treatment of Stage IVb Esophageal Squamous Cell Carcinoma
Lead sponsor
The First Affiliated Hospital of Xinxiang Medical College
Phase
Phase 2
Overall status
Unknown status
Start date
December 20, 2022
Completion date
December 20, 2024
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

escc